190 related articles for article (PubMed ID: 19801542)
1. Negative feedback Inhibition of NFATc1 by DYRK1A regulates bone homeostasis.
Lee Y; Ha J; Kim HJ; Kim YS; Chang EJ; Song WJ; Kim HH
J Biol Chem; 2009 Nov; 284(48):33343-51. PubMed ID: 19801542
[TBL] [Abstract][Full Text] [Related]
2. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.
Egusa H; Doi M; Saeki M; Fukuyasu S; Akashi Y; Yokota Y; Yatani H; Kamisaki Y
Bone; 2011 Aug; 49(2):264-74. PubMed ID: 21504804
[TBL] [Abstract][Full Text] [Related]
3. The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis.
Miyauchi Y; Ninomiya K; Miyamoto H; Sakamoto A; Iwasaki R; Hoshi H; Miyamoto K; Hao W; Yoshida S; Morioka H; Chiba K; Kato S; Tokuhisa T; Saitou M; Toyama Y; Suda T; Miyamoto T
J Exp Med; 2010 Apr; 207(4):751-62. PubMed ID: 20368579
[TBL] [Abstract][Full Text] [Related]
4. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
5. The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and maintains bone homeostasis through the mTORC1 pathway.
Ozaki K; Yamada T; Horie T; Ishizaki A; Hiraiwa M; Iezaki T; Park G; Fukasawa K; Kamada H; Tokumura K; Motono M; Kaneda K; Ogawa K; Ochi H; Sato S; Kobayashi Y; Shi YB; Taylor PM; Hinoi E
Sci Signal; 2019 Jul; 12(589):. PubMed ID: 31289211
[TBL] [Abstract][Full Text] [Related]
6. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
7. DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis.
Zhang Y; Su J; Wu S; Teng Y; Yin Z; Guo Y; Li J; Li K; Yao L; Li X
Sci Signal; 2015 Mar; 8(369):ra31. PubMed ID: 25805889
[TBL] [Abstract][Full Text] [Related]
8. Stimuli and Relevant Signaling Cascades for NFATc1 in Bone Cell Homeostasis: Friend or Foe?
Zhang Z; Wen H; Yang X; Zhang K; He B; Zhang X; Kong L
Curr Stem Cell Res Ther; 2019; 14(3):239-243. PubMed ID: 30516111
[TBL] [Abstract][Full Text] [Related]
9. IDH2 deficiency increases bone mass with reduced osteoclastogenesis by limiting RANKL expression in osteoblasts.
Lee SH; Lee SH; Lee JH; Park JW; Kim JE
Bone; 2019 Dec; 129():115056. PubMed ID: 31479775
[TBL] [Abstract][Full Text] [Related]
10. Regulators of G protein signaling 12 promotes osteoclastogenesis in bone remodeling and pathological bone loss.
Yuan X; Cao J; Liu T; Li YP; Scannapieco F; He X; Oursler MJ; Zhang X; Vacher J; Li C; Olson D; Yang S
Cell Death Differ; 2015 Dec; 22(12):2046-57. PubMed ID: 25909889
[TBL] [Abstract][Full Text] [Related]
11. Major vault protein (MVP) negatively regulates osteoclastogenesis via calcineurin-NFATc1 pathway inhibition.
Yuan L; Zhao N; Wang J; Liu Y; Meng L; Guo S; Wiemer EAC; Chen Q; Mao Y; Ben J; Ma J
Theranostics; 2021; 11(15):7247-7261. PubMed ID: 34158848
[No Abstract] [Full Text] [Related]
12. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
[TBL] [Abstract][Full Text] [Related]
13. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
[TBL] [Abstract][Full Text] [Related]
14. STAT3 controls osteoclast differentiation and bone homeostasis by regulating NFATc1 transcription.
Yang Y; Chung MR; Zhou S; Gong X; Xu H; Hong Y; Jin A; Huang X; Zou W; Dai Q; Jiang L
J Biol Chem; 2019 Oct; 294(42):15395-15407. PubMed ID: 31462535
[TBL] [Abstract][Full Text] [Related]
15. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis.
Kim Y; Sato K; Asagiri M; Morita I; Soma K; Takayanagi H
J Biol Chem; 2005 Sep; 280(38):32905-13. PubMed ID: 16046394
[TBL] [Abstract][Full Text] [Related]
16. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
17. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E plays crucial roles in maintaining bone mass by promoting osteoblast differentiation via ERK1/2 pathway and by suppressing osteoclast differentiation via c-Fos, NFATc1, and NF-κB pathway.
Noguchi T; Ebina K; Hirao M; Otsuru S; Guess AJ; Kawase R; Ohama T; Yamashita S; Etani Y; Okamura G; Yoshikawa H
Biochem Biophys Res Commun; 2018 Sep; 503(2):644-650. PubMed ID: 29906458
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin/NFAT signaling in osteoblasts regulates bone mass.
Winslow MM; Pan M; Starbuck M; Gallo EM; Deng L; Karsenty G; Crabtree GR
Dev Cell; 2006 Jun; 10(6):771-82. PubMed ID: 16740479
[TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.
Nishioku T; Kubo T; Kamada T; Okamoto K; Tsukuba T; Uto T; Shoyama Y
Biomed Res; 2020; 41(6):269-277. PubMed ID: 33268671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
